4.7 Article

Identification of RUNX1 as a Mediator of Aberrant Retinal Angiogenesis

期刊

DIABETES
卷 66, 期 7, 页码 1950-1956

出版社

AMER DIABETES ASSOC
DOI: 10.2337/db16-1035

关键词

-

资金

  1. National Institutes of Health [R01-EY-005318, R00-EY-021624, UH2NS100121-01, R21-EY-027061, K12-EY-16335, P30-EY-003790]
  2. American Diabetes Association Innovation Award [7-12-IN-11]
  3. Massachusetts Lions Eye Research Fund
  4. E. Matilda Ziegler Foundation for the Blind
  5. Karl Kirchgessner Foundation
  6. Department of Ophthalmology, Harvard Medical School
  7. Howard Hughes Medical Institute Medical Research Fellows Program
  8. Vascular Biology Program at Boston Children's Hospital

向作者/读者索取更多资源

Proliferative diabetic retinopathy (PDR) is a common cause of blindness in the developed world's working adult population and affects those with type 1 and type 2 diabetes. We identified Runt-related transcription factor 1 (RUNX1) as a gene upregulated in CD31(+) vascular endothelial cells obtained from human PDR fibrovascular membranes (FVMs) via transcriptomic analysis. In vitro studies using human retinal microvascular endothelial cells (HRMECs) showed increased RUNX1 RNA and protein expression in response to high glucose, whereas RUNX1 inhibition reduced HRMEC migration, proliferation, and tube formation. Immunohistochemical staining for RUNX1 showed reactivity in vessels of patient-derived FVMs and angiogenic tufts in the retina of mice with oxygen-induced retinopathy, suggesting that RUNX1 upregulation is a hallmark of aberrant retinal angiogenesis. Inhibition of RUNX1 activity with the Ro5-3335 small molecule resulted in a significant reduction of neovascular tufts in oxygen-induced retinopathy, supporting the feasibility of targeting RUNX1 in aberrant retinal angiogenesis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据